drugset / Trial / NCT07588139

A Study to Evaluate Dermal Open-Flow Microperfusion and Plasma Pharmacokinetic Study of Multiple Doses of Oral Povorcitinib or Topical Ruxolitinib Cream in Healthy Adult Participants

NCT07588139

Phase 1 Recruiting 24 enrolled Incyte Corporation
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the interstitial concentrations using the open-flow microperfusion device and plasma pharmacokinetics following multiple doses of povorcitinib or topical ruxolitinib cream in healthy adult participants.

Timeline

Start
2026-05-18
Primary completion
2026-09-03
Completion
2026-09-19

Drugs

EvaluationDrugModalityDoseRoute
Subject Povorcitinib Small molecule Oral
Subject Ruxolitinib Small molecule Topical

Indications

No indication recorded.